12:00 AM
 | 
Jan 25, 2010
 |  BC Week In Review  |  Company News  |  Deals

Biovel, Ranbaxy deal

Ranbaxy will acquire Biovel for an undisclosed sum. Biovel develops and markets biogenerics and biopharmaceuticals, including Typhoid Vi antigen vaccine against...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >